Search results for "VISCERAL ADIPOSITY"

PROPOSED OF A NEW SIMPLIFIED VISCERAL ADIPOSITY INDEX (VAI-2).

2015

Visceral Adiposity Index (VAI): A Reliable Indicator Of Visceral Fat Function Associated With Cardiometabolic Risk.

2010

Objective: To individuate a novel sex-specific index, based on Waist Circumference (WC), Body Mass Index (BMI), Triglycerides (TG) and HDL cholesterol (HDL), indirectly expressing visceral fat function. Research design and Methods: Visceral Adiposity Index (VAI) was first modelled on 315 non-obese healthy subjects. Using two multiple logistic regression models, VAI was retrospectively validated in 1,498 primary care patients in comparison to classical cardio and cerebrovascular risk factors. Results: All components of metabolic syndrome increased significantly across VAI quintiles. VAI was independently associated with both cardiovascular (OR:2.45; 95%CI: 1.52-3.95; p<0.001) and cerebrov…

HIGH VISCERAL ADIPOSITY INDEX (VAI) SCORE BEFORE AND AFTER TREATMENT IN YOUNGH HIV-POSITIVE PATIENTS

2013

The new therapies in HIV-positive patients are extremely effective in terms of immunological response. In western countries the mortality rate was reduced by 100% from 1984 to the current 8.8%. HIV people are now patients with a chronic disease characterized by also metabolic disorders. Long term virus alterations and treatment sideeffects induced lipid disorders, in particular hypercholesterolemia and hypertriglyceridemia. To assess cardiovascular risk (CVR) in HIV patients. From April 2012 to January 2013 we evaluated 20 HIV-positive naive patients, no HBV-HCV coinfected (19 males, age range 21-42 years, mean 31.8 + 4.8, BMI 23.5 + 3.8). Before and after inhibitor proteases (IP) treatment…

Visceral Adiposity Index: An Indicator of Adipose Tissue Dysfunction

2013

The Visceral Adiposity Index (VAI) has recently proven to be an indicator of adipose distribution and function that indirectly expresses cardiometabolic risk. In addition, VAI has been proposed as a useful tool for early detection of a condition of cardiometabolic risk before it develops into an overt metabolic syndrome. The application of the VAI in particular populations of patients (women with polycystic ovary syndrome, patients with acromegaly, patients with NAFLD/NASH, patients with HCV hepatitis, patients with type 2 diabetes, and general population) has produced interesting results, which have led to the hypothesis that the VAI could be considered a marker of adipose tissue dysfuncti…

Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients.

2012

Utilizzo del Visceral Adiposity Index per l’identificazione di donne con sindrome iperandrogenica a rischio cardiometabolico.

2012

Visceral Adiposity Index (VAI) as a simple indicator of “adipose tissue dysfunction” in patients with type 2 diabetes.

2013

Although still there is no a clear definition of “adipose tissue dysfunction”, the identification of clinical and biological markers of altered fat distribution and function may provide the needed tools to early identify a condition of cardiometabolic risk. Visceral Adiposity Index (VAI) is a mathematical gender-specific index estimated with the use of simple anthropometric [(BMI and Waist circumference (WC)] and biochemical parameters [HDL cholesterol (HDL) and Triglycerides (Tg)], that in recent studies has shown to reflect accurately the degree of visceral adiposity and insulin resistance. However, although VAI has been indirectly shown to be a marker of impaired fat distribution and fun…

Oligomenorrhea in PCOS is characterized by a high visceral adiposity index (VAI): a likely condition of cardiometabolic risk.

2011

One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus

2021

Introduction: This study investigates the effects of dapagliflozin on the visceral adiposity index (VAI), lipid accumulation product (LAP), product of triglycerides and glucose (TyG) and triglycerides to HDL-cholesterol ratio (TG/HDL-C) in patients with type 2 diabetes mellitus (T2D). Methods: In this real-life study, dapaglifozin was added to metformin alone (group 1, no. 42) or insulin plus metformin (group 2, no. 58) in 100 T2D patients. Results: In group 1, after 6 months of dapaglifozin addition, a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), systolic blood pressure (SBP) (p = 0.009), diastolic blood pressure (DBP) (p = 0.012), mean fasting blood…

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month…

2017

INTRODUCTION: Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes. METHODS: We selected 105 diabetic outpatients who were treated with liraglutide for at least 48 months as an add-on therapy to metformin alone (group A, n = 52) or insulin secretagogues (group B, n = 53) from diagnosis time. RESULTS: Altho…